Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 10Condylomata Acuminata 10Papillomavirus Infections 5Vulvar Neoplasms 3Vaginal Neoplasms 3Uterine Cervical Dysplasia 1Penile Neoplasms 1Neoplasms 1Cancer Survivor 1Anus Neoplasms 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 36Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 29Papillomavirus Vaccines 22Vaccines 11Human Papillomavirus Recombinant Vaccine nonavalent 11Radiotherapy, Intensity-Modulated 7Human Papillomavirus DNA Tests 7Colposcopy 7Cisplatin 7Educational Status 6Carboplatin 6Blood Specimen Collection 6Vaccines, Synthetic 5Specimen Handling 5Early Intervention, Educational 5Vaginal Smears 4Methods 4Engerix-B 4fludarabine 3epigallocatechin gallate 3artesunic acid 3artemisinin 3Watchful Waiting 3Surveys and Questionnaires 3Patient Navigation 3Paclitaxel 3Imiquimod 3Hepatitis A Vaccines 3Cyclophosphamide 3halofantrine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Papillomavirus Infections × Vaccines, Synthetic × Clear all
NCT05435209 2023-11-29

Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents

University of Washington

Phase 4 Completed
158 enrolled

Papillomavirus Infections

NCT01245764 2018-11-14

GARDASILâ„¢ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Merck Sharp & Dohme LLC

Phase 3 Completed
250 enrolled 20 charts
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

NCT00411749 2017-04-21

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

Merck Sharp & Dohme LLC

Phase 2 Completed
107 enrolled 12 charts

Papillomavirus Infections

NCT00496626 2017-04-17

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 3 Completed
600 enrolled 12 charts

Papillomavirus Infections

NCT00551187 2015-06-08

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
620 enrolled
Gynecologic

Uterine Cervical Neoplasms, Condylomata Acuminata, Vaginal Neoplasms, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡